复星医药(02196.HK):复宏汉霖(02696.HK)与Essex合作研发眼病新药
复星医药(02196.HK)公布,子公司复宏汉霖(02696.HK)计划与Essex Bio-Investment合作研发新药HLX04,用於湿性年龄相关性黄斑变性等眼病治疗,并於全球范围生产及商业化销售。
根据协议,复宏汉霖将主要负责该新药的临床前及临床试验、Essex 将主要负责许可产品的上市申请。复宏汉霖、Essex将按照20%、80%的比例承担合作开发的投入。根据约定,Essex应向复宏汉霖支付至多2,500万美元首付款及研发里程碑付款,并在商业化後支付销售里程碑付款及销售提成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.